 This is a Phase 1b, multicenter, open-label, dose-escalation study designed to estimate the maximum tolerated dose MTD and determine the recommended Phase 2 dose RP2D of ADXS31-164. Once the RP2D has been selected, up to 4 expansion cohorts will be evaluated. 